145 related articles for article (PubMed ID: 36842272)
21. Discovery and structure-activity relationship studies of 1-aryl-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione derivatives as potent dual inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and trytophan 2,3-dioxygenase (TDO).
Pan S; Zhou Y; Wang Q; Wang Y; Tian C; Wang T; Huang L; Nan J; Li L; Yang S
Eur J Med Chem; 2020 Dec; 207():112703. PubMed ID: 32871341
[TBL] [Abstract][Full Text] [Related]
22. Characterization of Apo-Form Selective Inhibition of Indoleamine 2,3-Dioxygenase*.
Ortiz-Meoz RF; Wang L; Matico R; Rutkowska-Klute A; De la Rosa M; Bedard S; Midgett R; Strohmer K; Thomson D; Zhang C; Mebrahtu M; Guss J; Totoritis R; Consler T; Campobasso N; Taylor D; Lewis T; Weaver K; Muelbaier M; Seal J; Dunham R; Kazmierski W; Favre D; Bergamini G; Shewchuk L; Rendina A; Zhang G
Chembiochem; 2021 Feb; 22(3):516-522. PubMed ID: 32974990
[TBL] [Abstract][Full Text] [Related]
23. The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1.
Panfili E; Mondanelli G; Orabona C; Gargaro M; Volpi C; Belladonna ML; Rossini S; Suvieri C; Pallotta MT
Front Immunol; 2023; 14():1134551. PubMed ID: 37122718
[TBL] [Abstract][Full Text] [Related]
24. Unique Sulfur-Aromatic Interactions Contribute to the Binding of Potent Imidazothiazole Indoleamine 2,3-Dioxygenase Inhibitors.
Peng YH; Liao FY; Tseng CT; Kuppusamy R; Li AS; Chen CH; Fan YS; Wang SY; Wu MH; Hsueh CC; Chang JY; Lee LC; Shih C; Shia KS; Yeh TK; Hung MS; Kuo CC; Song JS; Wu SY; Ueng SH
J Med Chem; 2020 Feb; 63(4):1642-1659. PubMed ID: 31961685
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel hydroxyamidine based indoleamine 2,3-dioxygenase 1 (IDO1) and thioredoxin reductase 1 (TrxR1) dual inhibitors.
Zhou J; Yu LZ; Fan YL; Guo CH; Lv XM; Zhou ZY; Huang HD; Miao DD; Zhang SP; Li XY; Zhao PP; Liu XP; Hu WH; Zhang C
Eur J Med Chem; 2023 Jan; 245(Pt 1):114860. PubMed ID: 36370550
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of biaryl alkyl ethers as inhibitors of IDO1.
Markwalder JA; Balog AJ; Williams DK; Nara SJ; Reddy R; Roy S; Kanyaboina Y; Li X; Johnston K; Fan Y; Lewis H; Marsilio F; Yan C; Critton D; Newitt JA; Traeger SC; Wu DR; Jure-Kunkel MN; Jayaraman L; Lin TA; Sinz MW; Hunt JT; Seitz SP
Bioorg Med Chem Lett; 2023 May; 88():129280. PubMed ID: 37054759
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
[TBL] [Abstract][Full Text] [Related]
28. Discovery of 5-(pyridin-3-yl)-1H-indole-4,7-diones as indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Kong KM; Zhang JW; Liu BZ; Meng GR; Zhang Q
Bioorg Med Chem Lett; 2020 Feb; 30(4):126901. PubMed ID: 31882299
[TBL] [Abstract][Full Text] [Related]
29. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
30. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
Kristeleit R; Davidenko I; Shirinkin V; El-Khouly F; Bondarenko I; Goodheart MJ; Gorbunova V; Penning CA; Shi JG; Liu X; Newton RC; Zhao Y; Maleski J; Leopold L; Schilder RJ
Gynecol Oncol; 2017 Sep; 146(3):484-490. PubMed ID: 28698009
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines Expressing Either Murine or Human IDO1 or TDO2.
Tijono SM; Palmer BD; Tomek P; Flanagan JU; Henare K; Gamage S; Braun L; Ching LM
Pharmaceuticals (Basel); 2022 Aug; 15(9):. PubMed ID: 36145311
[TBL] [Abstract][Full Text] [Related]
32. Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1.
Paul S; Roy A; Deka SJ; Panda S; Trivedi V; Manna D
Eur J Med Chem; 2016 Oct; 121():364-375. PubMed ID: 27267006
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and structure-activity relationship study of novel naphthoindolizine and indolizinoquinoline-5,12-dione derivatives as IDO1 inhibitors.
Yang R; Chen Y; Pan L; Yang Y; Zheng Q; Hu Y; Wang Y; Zhang L; Sun Y; Li Z; Meng X
Bioorg Med Chem; 2018 Sep; 26(17):4886-4897. PubMed ID: 30170925
[TBL] [Abstract][Full Text] [Related]
34. Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy.
Yan D; Xu J; Wang X; Zhang J; Zhao G; Lin Y; Tan X
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563059
[TBL] [Abstract][Full Text] [Related]
35. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
Front Immunol; 2021; 12():661357. PubMed ID: 33828565
[TBL] [Abstract][Full Text] [Related]
36. Advances in the discovery and development of selective heme-displacing IDO1 inhibitors.
Sun L
Expert Opin Drug Discov; 2020 Oct; 15(10):1223-1232. PubMed ID: 32568559
[TBL] [Abstract][Full Text] [Related]
37. Structural Basis of Selective Human Indoleamine-2,3-dioxygenase 1 (hIDO1) Inhibition.
Kassab SE; Mowafy S
ChemMedChem; 2021 Oct; 16(20):3149-3164. PubMed ID: 34174026
[TBL] [Abstract][Full Text] [Related]
38. Discovery and characterization of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening.
Guo W; Yao S; Sun P; Yang TB; Tang CP; Zheng MY; Ye Y; Meng LH
Acta Pharmacol Sin; 2020 Mar; 41(3):423-431. PubMed ID: 31197246
[TBL] [Abstract][Full Text] [Related]
39. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 5-(N-hydroxycarbamimidoyl) benzofuran derivatives as novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
Jung J; Yoon H; Sohn TI; Jang K; Yoo Y; Jeong I; Shin JE; Lee JH; Ann J; Lee J
Bioorg Med Chem Lett; 2021 May; 40():127963. PubMed ID: 33741464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
